Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ,III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma: A Randomized, Controlled Clinical Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ,III of locally advanced HER-2 Positive adenocarcinoma at gastroesophageal junction
Epistemonikos ID: 01b72f1ace5858dae36b4ad90ff52b900d647d03
First added on: May 21, 2024